1. An electromagnetic stirrer of molten steel disposed at a distance of less than 9 m upstream, in the casting direction, of a reduction rolling position of a slab with a liquid core to stir molten steel of the liquid core in a width-wise direction of the slab, comprising:
an iron core disposed with its length-wise axis along a width-wise direction of slab; and
a plurality of exciting coils that are wound around the outer circumference of and about a length-wise axis of the iron core, in which
two-phase or three-phase alternating current is passed through the exciting coils, and
when imparting a stirring flow which causes molten steel to flow from both minor sides of slab toward the width-wise center, of slab so as to collide with each other in the vicinity of the width-wise center of slab, the phases of current in the exciting coils are distributed symmetrically, with respect to the iron core length-wise center position corresponding to the width-wise center of slab, along a length-wise direction of the iron core,
when imparting a stirring flow which causes molten steel to flow from one minor side of the slab toward the other minor side thereof while reversing the flowing direction at a predetermined time interval, the phases of current in exciting coils are distributed in such a manner that the phase of current of exciting coils at one width-wise end portion of iron core increases or decreases by 90 or 60\xb0 sequentially from that at the other width-wise end portion, and
the stirring flow is selectively imparted.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for treating benign prostatic hyperplasia comprising the steps of:
(a) orally administering to a patient having benign prostatic hyperplasia a therapeutically effective amount of an alpha-1 adrenoceptor blocking agent, and
(b) orally administering to said patient a therapeutically effective amount of 13-cis-retinoic acid.
2. The method of claim 1, wherein said alpha-1 adrenoceptor blocking agent is tamsulosin hydrochloride.
3. The method of claim 1, wherein said alpha-1 adrenoceptor blocking agent is terazosin hydrochloride.
4. The method of claim 1, wherein said alpha-1 adrenoceptor blocking agent is alfuzosin hydrochloride.
5. The method of claim 1, wherein said alpha-1 adrenoceptor blocking agent is doxazosin mesylate.
6. The method of claim 1, wherein step (b) further comprises orally administering to said patient an initial dosage of about 0.25 mg per pound of body weight of 13-cis-retinoic acid for an initial treatment period, and thereafter orally administering a sustaining dosage of about 0.25 mg per pound of body weight of 13-cis-retinoic acid about every five to seven days in a sustaining period.
7. The method of claim 6, wherein said initial treatment period is from about ten days to about twenty days.
8. The method of claim 7, wherein said sustaining period is about one year.
9. The method of claim 1, wherein said 13-cis-retinoic acid is in a pharmaceutical composition comprising a pharmaceutical acceptable medium.
10. The method of claim 9, wherein said pharmaceutical composition is in a form selected from the group consisting of powder, pill, capsule, tablet and liquid.
11. A method for treating benign prostatic hyperplasia comprising the steps of:
(a) orally administering to a patient having benign prostatic hyperplasia a therapeutically effective amount of an inhibitor of steroid 5(alpha)-reductase, and
(b) orally administering to said patient a therapeutically effective amount of 13-cis-retinoic acid.
12. The method of claim 11, wherein said inhibitor of steroid 5(alpha)-reductase is finasteride.
13. The method of claim 11, wherein said inhibitor of steroid 5(alpha)-reductase is dutasteride.
14. The method of claim 11, wherein step (b) further comprises orally administering to said patient an initial dosage of about 0.25 mg per pound of body weight of 13-cis-retinoic acid for an initial treatment period, and thereafter orally administering a sustaining dosage of about 0.25 mg per pound of body weight of 13-cis-retinoic acid about every five to seven days in a sustaining period.
15. The method of claim 14, wherein said initial treatment period is from about ten days to about twenty days.
16. The method of claim 15, wherein said sustaining period is about one year.
17. The method of claim 11, wherein said 13-cis-retinoic acid is in a pharmaceutical composition comprising a pharmaceutical acceptable medium.
18. The method of claim 17, wherein said pharmaceutical composition is in a form selected from the group consisting of powder, pill, capsule, tablet and liquid.
19. A method for treating benign prostatic hyperplasia comprising the steps of:
(a) orally administering to a patient having benign prostatic hyperplasia a therapeutically effective amount of 13-cis-retinoic acid; and
(a) orally administering to said patient a therapeutically effective amount of plant sterols.